Page 51 - Characterization of genetic neurodevelopmental disorders at adult age, with a focus on 22q11.2 deletion syndrome - Emma Boersma

Parkinsonism in GNDs
Financial disclosures related to this manuscript
None.
Financial disclosures for the previous 12 months, not related to this
manuscript
Erik Boot and Thérèse van Amelsvoort are on the advisory board of the
22q11 society and Stichting Steun 22q11. Tom de Koning is medical advisor
for three non-profit charities: Stofwisselingskracht foundation (Stichting
Stofwisselingskracht), North Sea myoclonus foundation (Stichting
Noordzeeziekte) and JanIvo Foundation (janivo stichting). Tom de Koning
is also medical advisor of Ancora Health BV (profit), a Dutch company
delivering lifestyle advise of which he also holds shares. Agnies van Eeghen
is chair of the scientific advisory board of the Dutch TSC Foundation, medical
advisor of Jazz pharmaceuticals, and is affiliated with European Reference
Network ITHACA. The other authors have no disclosures to report.
Competing interests
The authors report no competing interests.
Ethical compliance statement
We confirm that we have read the Journal’s position on issues involved
in ethical publication and affirm that this work is consistent with those
guidelines. The authors confirm that the approval of an institutional review
board was not required for this work. The authors confirm that patient
consent was not required for this work.
Supplementary material
Additional data is available in the Supplementary Material (online).
2
49